Literature DB >> 21735252

New insights into glioma classification based on isocitrate dehydrogenase 1 and 2 gene status.

Ichiyo Shibahara1, Yukihiko Sonoda, Masayuki Kanamori, Ryuta Saito, Toshihiro Kumabe, Teiji Tominaga.   

Abstract

In glioma, mutations in the isocitrate dehydrogenase 1 and 2 (IDH1/2) genes have been receiving attention. IDH1/2 mutations are frequently found in grade II and III gliomas. These genetic alterations occur very early in gliomagenesis and strongly predict favorable outcome in patients with high-grade gliomas. Despite the evolution of studies on this topic, the underlying mechanism of the IDH1/2 mutations remains unknown. Here, we briefly review the current knowledge of IDH1/2 and discuss molecular diagnostics based on IDH1/2 gene status.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21735252     DOI： 10.1007/s10014-011-0050-4

Source DB:  PubMed          Journal:  Brain Tumor Pathol        ISSN： 1433-7398            Impact factor:   3.154


  4 in total

1.  Malignant clinical features of anaplastic gliomas without IDH mutation.

Authors:  Ichiyo Shibahara; Yukihiko Sonoda; Takuhiro Shoji; Masayuki Kanamori; Ryuta Saito; Tomoo Inoue; Tomohiro Kawaguchi; Yoji Yamashita; Takashi Watanabe; Toshihiro Kumabe; Mika Watanabe; Hiroyoshi Suzuki; Teiji Tominaga
Journal:  Neuro Oncol       Date:  2014-06-23       Impact factor: 12.300

2.  CDKN2A loss is associated with shortened overall survival in lower-grade (World Health Organization Grades II-III) astrocytomas.

Authors:  Gerald F Reis; Melike Pekmezci; Helen M Hansen; Terri Rice; Roxanne E Marshall; Annette M Molinaro; Joanna J Phillips; Hannes Vogel; John K Wiencke; Margaret R Wrensch; Kyle M Walsh; Arie Perry
Journal:  J Neuropathol Exp Neurol       Date:  2015-05       Impact factor: 3.685

Review 3.  The Oncogenesis of Glial Cells in Diffuse Gliomas and Clinical Opportunities.

Authors:  Qiyuan Zhuang; Hui Yang; Ying Mao
Journal:  Neurosci Bull       Date:  2022-10-13       Impact factor: 5.271

4.  Genetic alterations of IDH1 and Vegf in brain tumors.

Authors:  Silvia Veganzones; Virginia de la Orden; Lucía Requejo; Beatriz Mediero; María Luisa González; Náyade Del Prado; Carmen Rodríguez García; Raquel Gutiérrez-González; Alvaro Pérez-Zamarrón; Armando Martínez; Marisa L Maestro; Horacio Mario Zimman; Anna González-Neira; Jesús Vaquero; Gregorio Rodríguez-Boto
Journal:  Brain Behav       Date:  2017-08-01       Impact factor: 2.708
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.